Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Study Overview

The purpose of this study is to determine the effectiveness of progesterone given by mouth for minimizing drug EKG response to a drug.

Study Description

Our objective is to evaluate and compare the efficacy of novel therapeutic approaches to reduce the risk of drug-induced QTc interval prolongation and TdP.

Additional Information

Participants will be paid for their participation.

IRB Number: 1806935117
Research Study Identifier: TX9173
Principal Investigator: James Tisdale

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Study Overview

Study Description

Additional Information

Recruitment Status

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Study Overview

Study Description

Additional Information

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required